Gene Therapy Tested in People With X-linked Retinitis Pigmentosa
Tests FT-002, a gene therapy injected into the eye, in people with X-linked retinitis pigmentosa.
Plain-language title generated from the registry record
Registry title: Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Key facts
- Where
- Beijing and Shanghai, ChinaSee the 2 sites
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 45 years old?
Source: NCT05874310, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
- Eye ENT Hospital of Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Frontera Therapeutics
- Trial code
- NCT05874310
- Record updated
- 24 May 2023
- Original description
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).Read full original descriptionShow less
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Inclusion: 1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR .
Exclusion: 1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.